Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Galena Biopharma GALE

Healthcare Biotechnology
"Galena Biopharma is a biopharmaceutical company. Its main activity is the development and commercialization of hematology and oncology therapies. Its pipeline includes products targeting hematology diseases, breast cancer, gastric cancer, and gynecological cancer. The company’s cancer immunotherapy consists of two areas: prevention of cancer reoccurrence and primary prevention of invasive... see more

Bullboard (NDAQ:GALE)

View:
Prev 1 2 3 4
Post by MissionIRon Aug 09, 2013 5:17pm

Galena Biopharma, Inc. (GALE) Reports Q2 Achievements, Financial Results

Galena Biopharma, Inc. (GALE) Reports Q2 Achievements, Financial Results Galena Biopharma, a biopharmaceutical company commercializing and developing targeted oncology treatments that address major ...more  
237
Post by MissionIRon Aug 08, 2013 4:37pm

Needham Gives ‘Buy’ Rating to Galena Biopharma, Inc. (GALE), Predicts $3.50 Stock Price

Needham Gives ‘Buy’ Rating to Galena Biopharma, Inc. (GALE), Predicts $3.50 Stock Price Nationally recognized investment banking and asset management firm Needham & Company LLC ...more  
222
Post by MissionIRon Aug 07, 2013 6:33pm

Seeking Alpha Publishes Article Featuring Galena Biopharma, Inc. (GALE)

Seeking Alpha Publishes Article Featuring Galena Biopharma, Inc. (GALE) Galena Biopharma, Inc., a biopharmaceutical company focused on developing and commercializing targeted oncology treatments to ...more  
276
Post by MissionIRon Aug 05, 2013 6:21pm

JMP Securities Provides Detailed Valuation of Galena Biopharma, Inc. (GALE)

JMP Securities Provides Detailed Valuation of Galena Biopharma, Inc. (GALE) JMP Securities recently initiated coverage on Galena Biopharma, Inc. with a market outperform rating and a $5 price target ...more  
312
Post by MissionIRon Aug 02, 2013 6:58pm

Analysts Predict $5 Stock Price for Galena Biopharma, Inc. (GALE)

Analysts Predict $5 Stock Price for Galena Biopharma, Inc. (GALE) As of Aug. 1, 2013, biopharmaceutical company Galena Biopharma was trading at a price of $2.09 – but analysts have predicted a target ...more  
210
Post by MissionIRon Aug 01, 2013 8:02pm

Galena Biopharma, Inc. (GALE) Data from Phase Ib Trial of FBP Peptide Vaccine is Very Encouraging

Galena Biopharma, Inc. (GALE) Data from Phase Ib Trial of FBP Peptide Vaccine is Very Encouraging As biopharmaceutical company Galena Biopharma continues the dose escalation Phase Ib trial of its FBP ...more  
148
Post by MissionIRon Aug 01, 2013 7:59pm

Senior Biotechnology Analyst Provides Personal Perspective on Galena Biopharma, Inc. (GALE)

Senior Biotechnology Analyst Provides Personal Perspective on Galena Biopharma, Inc. (GALE) In a recent article published by The Life Sciences Report, Cantor Fitzgerald Senior Biotechnology Analyst ...more  
168
Post by MissionIRon Jul 31, 2013 4:23pm

Updates from Galena Biopharma, Inc. (GALE)

Updates from Galena Biopharma, Inc. (GALE) Biopharmaceutical company Galena Biopharma has moved forward with its Phase IIb trial of NeuVax (nelipepimut-S or E75) combined with Herceptin as an adjuvant ...more  
226
Post by MissionIRon Jul 30, 2013 8:33am

Updated 36-Slide Presentation Now Available

Updated 36-Slide Presentation Now Availablehttps://GALE.MissionIR.com Please read full disclaimers at https://disclaimer.missionir.com
105
Post by MissionIRon Jul 29, 2013 7:40pm

Progress in Galena Biopharma’s (GALE) Phase 1/2 Study with FBP Cancer Vaccine

Progress in Galena Biopharma’s (GALE) Phase 1/2 Study with FBP Cancer Vaccine Biopharmaceutical company Galena Biopharma, Inc. continues its ongoing Phase 1/2 dosing and safety ...more  
237
Post by EarningsImpact1on Jul 29, 2013 3:59am

JMP-Securities-2013-Healthcare-Conference updates

Priority is getting NeuVax approved and context for this is 210,000 women a year in US, will be newly diagnosed for breast cancer. [url=https://www.earningsimpact.com/Transcript/82090/GALE/Galena ...more  
232
Post by MissionIRon Jul 25, 2013 4:37pm

Galena Biopharma, Inc. (GALE) is “One to Watch”

Galena Biopharma, Inc. (GALE) is “One to Watch” Galena Biopharma is focused on developing and commercializing targeted oncology treatments to address major unmet medical ...more  
187
Comment by RockLobster1on Apr 29, 2013 9:16pm

RE: Will patience be rewarded?

I bought this a few weeks back on the chart pattern.,.. looking very positive but maybe I need to watch out for results that could move it....  good luck
125
Discussion
Post by brent77on Feb 12, 2013 11:48am

Will patience be rewarded?

These pharmaceuticals always suck me in, and I tie up some of my play money. I at least have to wait now until Trial III of NeuVax, right?
202
Prev 1 2 3 4
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities